Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations.

Varanasi A, Chaudhuri A, Dhindsa S, Arora A, Lohano T, Vora MR, Dandona P

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Mar 2011Cited by 30 (Europe PMC)

PMID20841306DOI10.4158/ep10199.orPepBankPUB-20841306

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide treatment was linked to lower A1C from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide treatment was linked to lower long-term blood sugar from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C
Study
n = 141
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 1.4 yearsAs given in this study (human).
Measurements
A1C reduction
0.7%
exenatide
Source sentences
Summary
Exenatide (mean duration of treatment, 1.4 years) decreased A1C (0.7%), weight (5 kg), systolic BP (8 mm Hg), and triglyceride concentrations (46 mg/dL) (P<.05 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130601
02HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide treatment was linked to lower weight from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide treatment was linked to lower weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBody weight
Study
n = 141
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · mean 1.4 yearsAs given in this study (human).
Measurements
Weight reduction
5 kg
exenatide
Source sentences
Summary
Exenatide (mean duration of treatment, 1.4 years) decreased A1C (0.7%), weight (5 kg), systolic BP (8 mm Hg), and triglyceride concentrations (46 mg/dL) (P<.05 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130602
03HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide treatment was linked to lower systolic blood pressure from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide treatment was linked to lower systolic blood pressure from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic blood pressure
Study
n = 141
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · mean 1.4 yearsAs given in this study (human).
Measurements
Systolic BP reduction
8 mm Hg
exenatide
Source sentences
Summary
Exenatide (mean duration of treatment, 1.4 years) decreased A1C (0.7%), weight (5 kg), systolic BP (8 mm Hg), and triglyceride concentrations (46 mg/dL) (P<.05 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130603
04HumanObservational studyEfficacy outcome
In patients with type 2 diabetes, exenatide treatment was linked to lower triglycerides from baseline.
In plain wordsIn patients with type 2 diabetes, exenatide treatment was linked to lower triglycerides from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides
Study
n = 141
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · mean 1.4 yearsAs given in this study (human).
Measurements
Triglyceride reduction
46 mg/dL
exenatide
Source sentences
Summary
Exenatide (mean duration of treatment, 1.4 years) decreased A1C (0.7%), weight (5 kg), systolic BP (8 mm Hg), and triglyceride concentrations (46 mg/dL) (P<.05 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130604
05HumanObservational studyEfficacy outcome
In patients continuing exenatide, treatment was linked to lower weight from baseline.
In plain wordsIn patients continuing exenatide, treatment was linked to lower weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight in continued-treatment subgroup
Study
n = 61
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · mean 2.4 yearsAs given in this study (human).
Measurements
Weight reduction
7 kg
continued exenatide
Source sentences
Summary
Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-one patients continued exenatide therapy throughout the study (mean duration of use, 2.4 years).
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130605
06HumanObservational studyEfficacy outcome
In patients continuing exenatide, treatment was linked to lower systolic blood pressure from baseline.
In plain wordsIn patients continuing exenatide, treatment was linked to lower systolic blood pressure from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSystolic BP in continued-treatment subgroup
Study
n = 61
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · mean 2.4 yearsAs given in this study (human).
Measurements
Systolic BP reduction
8 mm Hg
continued exenatide
Source sentences
Summary
Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-one patients continued exenatide therapy throughout the study (mean duration of use, 2.4 years).
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130606
07HumanObservational studyEfficacy outcome
In patients continuing exenatide, treatment was linked to lower triglycerides from baseline.
In plain wordsIn patients continuing exenatide, treatment was linked to lower triglycerides from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTriglycerides in continued-treatment subgroup
Study
n = 61
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · mean 2.4 yearsAs given in this study (human).
Measurements
Triglyceride reduction
52 mg/dL
continued exenatide
Source sentences
Summary
Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-one patients continued exenatide therapy throughout the study (mean duration of use, 2.4 years).
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130607
08HumanObservational studyEfficacy outcome
In patients continuing exenatide, treatment was linked to lower A1C from baseline.
In plain wordsIn patients continuing exenatide, treatment was linked to lower long-term blood sugar from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseA1C in continued-treatment subgroup
Study
n = 61
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · mean 2.4 yearsAs given in this study (human).
Measurements
A1C reduction
1.3%
continued exenatide
Source sentences
Summary
Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-one patients continued exenatide therapy throughout the study (mean duration of use, 2.4 years).
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130608
09HumanObservational studyEfficacy outcome
In patients continuing exenatide, treatment was linked to lower CRP from baseline.
In plain wordsIn patients continuing exenatide, treatment was linked to lower C-reactive protein from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseCRP in continued-treatment subgroup
Study
n = 61
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · mean 2.4 yearsAs given in this study (human).
Measurements
CRP reduction
2.4 mg/L
continued exenatide
Source sentences
Summary
Exenatide treatment reduced their mean weight by 7 kg, systolic BP by 8 mm Hg, triglycerides by 52 mg/dL, A1C by 1.3%, and CRP by 2.4 mg/L (P<.05 for all).
2 context sentences(design, population, supporting numbers)
Summary · context
Sixty-one patients continued exenatide therapy throughout the study (mean duration of use, 2.4 years).
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130609
10HumanObservational studyOther
In exenatide-treated patients with type 2 diabetes, systolic blood pressure reductions were not related to weight loss.
In plain wordsIn patients receiving exenatide, lower systolic blood pressure was not linked to weight loss.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSystolic BP reduction and weight loss association
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Reductions in systolic BP and CRP were not related to weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130610
11HumanObservational studyOther
In exenatide-treated patients with type 2 diabetes, CRP reductions were not related to weight loss.
In plain wordsIn patients receiving exenatide, lower C-reactive protein was not linked to weight loss.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCRP reduction and weight loss association
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
Reductions in systolic BP and CRP were not related to weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130611
12HumanObservational studyOther
In exenatide-treated patients, CRP reduction was positively related to baseline CRP.
In plain wordsIn patients receiving exenatide, a larger C-reactive protein reduction was linked to higher baseline levels.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCRP reduction and baseline CRP association
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
Correlation r
0.78 unitless
CRP reduction versus baseline CRP
Source sentences
Summary
The reduction in CRP concentration was significantly related to the baseline CRP concentration (r = 0.78; P<.001) and to change in A1C (r = 0.68; P = .02).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130612
13HumanObservational studyOther
In exenatide-treated patients, CRP reduction was positively related to A1C change.
In plain wordsIn patients receiving exenatide, C-reactive protein reduction was linked to the change in long-term blood sugar.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCRP reduction and A1C change association
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
Correlation r
0.68 unitless
CRP reduction versus A1C change
Source sentences
Summary
The reduction in CRP concentration was significantly related to the baseline CRP concentration (r = 0.78; P<.001) and to change in A1C (r = 0.68; P = .02).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130613
14HumanObservational studyOther
In patients with type 2 diabetes, benefits reversed within 6 months after exenatide cessation.
In plain wordsIn patients with type 2 diabetes, benefits reversed within 6 months after exenatide treatment stopped.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableBenefit reversal after cessation
Study
n: not reported in source
Outcome group
Overall treatment effect · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Patients who stopped taking exenatide had a reversal of the benefits within 6 months after cessation of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a retrospective review of 141 patients with type 2 diabetes mellitus treated with exenatide at a tertiary clinic.
Report a problemFND-2084130614

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01722266

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

University at Buffalon = 721 Nov 2012 to 1 Dec 2014

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 5 Jan 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.